Vikor Scientific
Vikor Scientific is a market leader in providing targeted, molecular diagnostics that aim to improve clinical and economic outcomes. The company focuses on developing solutions to combat antibiotic resistance through innovative molecular pathogen detection, offering laboratory services, integrated solutions for antibiotic stewardship, analytics, research & development, and career opportunities. Vikor emphasizes rapid, accurate diagnostics within 24 hours to enable better treatment decisions, reduce unnecessary antibiotic use, and improve patient outcomes. The company is actively involved in community engagement, industry partnerships, and advancing scientific research, including publications on COVID-19, cancer research, and respiratory infections.
Industries
Nr. of Employees
large (251-1000)
Vikor Scientific
22 WestEdge Street, 8th Floor, Charleston, SC 29403
Products
Targeted respiratory pathogen panel
Molecular panel for detection of respiratory pathogens and associated resistance markers.
Gastrointestinal pathogen panel
Molecular testing panel focused on enteric bacterial, viral, and parasitic pathogens.
Dermatologic infection pathogen panel
Molecular panel for pathogens relevant to skin and soft tissue infections.
Joint infection panel
Molecular testing for pathogens implicated in joint and prosthetic infections.
Nail fungal pathogen panel
Molecular assay set for identification of fungal organisms causing onychomycosis.
Pharmacogenetics panel
Genetic testing panel to assess drug response markers for personalized therapy decisions.
Targeted respiratory pathogen panel
Molecular panel for detection of respiratory pathogens and associated resistance markers.
Gastrointestinal pathogen panel
Molecular testing panel focused on enteric bacterial, viral, and parasitic pathogens.
Dermatologic infection pathogen panel
Molecular panel for pathogens relevant to skin and soft tissue infections.
Joint infection panel
Molecular testing for pathogens implicated in joint and prosthetic infections.
Nail fungal pathogen panel
Molecular assay set for identification of fungal organisms causing onychomycosis.
Pharmacogenetics panel
Genetic testing panel to assess drug response markers for personalized therapy decisions.
Services
Central laboratory service performing molecular pathogen identification and resistance gene testing from provider-submitted specimens.
PharmD consultation service that reviews molecular results and provides treatment recommendations and stewardship guidance.
Programs combining diagnostic data, analytics, and clinical guidance to support appropriate antibiotic use.
Digital portals for provider account management, ordering supplies, scheduling pickup requests, and online payments.
Participation in clinical and translational research projects and dissemination of findings via publications and trend reports.
Central laboratory service performing molecular pathogen identification and resistance gene testing from provider-submitted specimens.
PharmD consultation service that reviews molecular results and provides treatment recommendations and stewardship guidance.
Programs combining diagnostic data, analytics, and clinical guidance to support appropriate antibiotic use.
Digital portals for provider account management, ordering supplies, scheduling pickup requests, and online payments.
Participation in clinical and translational research projects and dissemination of findings via publications and trend reports.
Expertise Areas
- Rapid molecular diagnostics
- Antibiotic resistance testing and stewardship
- Clinical pharmacotherapy consultation
- Targeted pathogen panel development
Key Technologies
- Molecular diagnostics
- Polymerase Chain Reaction (PCR)
- Resistance gene detection assays
- Semi-quantitative molecular assays
News & Updates
A significant innovation announcement related to cancer treatments and precision medicine is scheduled at the SCBIO conference, which is experiencing record registration and industry growth.
Alison is recognized for her integrity, work ethic, and positive attitude on the Rejections Team.
Anthony is recognized for his efforts to improve business insight and his dedication to problem-solving.
William is recognized for his quick adaptation, communication skills, and positive attitude.
Research on COVID-19, highlighting the need for new diagnostics, therapeutics, and healthcare infrastructure.
Study on the prevalence of respiratory co-infections in COVID-19 patients in the US.
A significant innovation announcement related to cancer treatments and precision medicine is scheduled at the SCBIO conference, which is experiencing record registration and industry growth.
Alison is recognized for her integrity, work ethic, and positive attitude on the Rejections Team.
Anthony is recognized for his efforts to improve business insight and his dedication to problem-solving.
William is recognized for his quick adaptation, communication skills, and positive attitude.
Research on COVID-19, highlighting the need for new diagnostics, therapeutics, and healthcare infrastructure.
Study on the prevalence of respiratory co-infections in COVID-19 patients in the US.